Also listed on Aerogen, Inc., an earlier holder on the record. The recorded assignments below show how it moved.
Term ends Aug 15, 2030 · High confidence
20-year base term ended Apr 27, 2024
Held by Novartis AG
Filed Apr 27, 2004 as application 10/833,932 · Granted Dec 31, 2013
Base term plus 2301 days of patent term adjustment (USPTO delay)
Today
2004
2030
Clock starts
Apr 27, 2004
Apr 27, 2004
Term ends
Aug 15, 2030
Aug 15, 2030
Granted
Dec 31, 2013
Dec 31, 2013
base term
patent term adjustment
fee events
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
2,301
Days of term adjustment
Read from the USPTO patent term adjustment record, not recalculated here.
None
Terminal disclaimer
No disclaimer on this record.
3 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
2
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term runs 2301 days past its 20-year base term on prosecution delay. All three maintenance fees are recorded paid; no more fees are due. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Apr 27, 2004, when this application, 10/833,932, was filed | Apr 27, 2024 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | +2301 days, USPTO patent term adjustment record | Aug 15, 2030 | High confidence |
| Terminal disclaimer cap | None on record | no cap applied | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 3 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Aug 15, 2030 | High confidence |
This family
| US 8,616,195 | this patent Aug 2030 | Aug 2030 |
| Application PCT/US2004/021628 | PCT application no patent term | no patent term |
The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Aug 30, 2004 Reel 15752, frame 27 | Power, John; Moran, Declan; Devery, Donal; O'sullivan, Gavan; Fink, James; Smith, Niall | Aerogen, Inc. | Assignment of Assignor's Interest |
| Jan 7, 2009 Reel 22062, frame 905 | Aerogen, Inc. | Novartis Pharma AG | Assignment of Patent Rights |
| Nov 21, 2013 Reel 31648, frame 528 | Novartis Pharma AG | Novartis AG | Assignment of Assignor's Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
What's changing
Aug 2030
Term ends Aug 15, 2030. No further fees fall due before then
Note
The 2301 days of patent term adjustment (USPTO delay) are read from the USPTO record, not recalculated by us
Citations
172
later US patents cite this one
That is top 5% of utility patents granted in 2013 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.